Agile Therapeutics Inc (AGRX) : Jasper Ridge Partners has sold out all of its stake in Agile Therapeutics Inc during the most recent quarter, according to the disclosure filed by the company on Nov 14, 2016 with the SEC. The investment management company has sold out 12,160 shares of Agile Therapeutics Inc which is valued at $85,120.
Other Hedge Funds, Including , Manufacturers Life Insurance Company The reduced its stake in AGRX by selling 1,858 shares or 68.51% in the most recent quarter. The Hedge Fund company now holds 854 shares of AGRX which is valued at $6,140.Geode Capital Management boosted its stake in AGRX in the latest quarter, The investment management firm added 25,833 additional shares and now holds a total of 114,079 shares of Agile Therapeutics Inc which is valued at $757,485.Aisling Capital reduced its stake in AGRX by selling 308,342 shares or 11.93% in the most recent quarter. The Hedge Fund company now holds 2,275,455 shares of AGRX which is valued at $15,109,021. Agile Therapeutics Inc makes up approx 3.70% of Aisling Capital’s portfolio.Tiaa Cref Investment Management boosted its stake in AGRX in the latest quarter, The investment management firm added 1,513 additional shares and now holds a total of 41,054 shares of Agile Therapeutics Inc which is valued at $309,137. Hamilton Lane Advisors added AGRX to its portfolio by purchasing 55,385 company shares during the most recent quarter which is valued at $401,541. Agile Therapeutics Inc makes up approx 0.21% of Hamilton Lane Advisors’s portfolio.
Agile Therapeutics Inc opened for trading at $7.12 and hit $7.31 on the upside on Monday, eventually ending the session at $7.19, with a gain of 1.55% or 0.11 points. The heightened volatility saw the trading volume jump to 1,82,955 shares. Company has a market cap of $207 M.
Agile Therapeutics Inc. is a women’s health specialty pharmaceutical company. The Company is engaged in the development and commercialization of prescription contraceptive products. The Company’s product candidates are designed to provide women with contraceptive options. The Company has developed a transdermal patch technology called Skinfusion. The Company’s lead product candidate Twirla also known as AG200-15 is a once-weekly prescription contraceptive patch in Phase III clinical development. Twirla is a combined hormonal contraceptive (CHC) patch that contains the active ingredients ethinyl estradiol (EE) which is a synthetic estrogen and levonorgestrel (LNG) which is a type of progestin a synthetic steroid hormone. Twirla is designed using the Company’s Skinfusion technology to consistently deliver both hormones over a seven-day period at levels. The Company is also developing transdermal contraceptive products including AG200-ER AG200-SP and AG890.